Bevacizumab

You have access
Effectiveness of Hyperthermia as Monotherapy and Adjuvant Therapy Approaches Against an In Vitro Model of Colorectal Carcinoma
GEORGIOS PETRAKIS, THEODORA MANTSO, MICHAIL I. KOUKOURAKIS, MIHALIS I. PANAYIOTIDIS and SOTIRIS BOTAITIS

Anticancer Research May 2022, 42 (5) 2363-2374; DOI: https://doi.org/10.21873/anticanres.15715
You have access
Bevacizumab-based Salvage Chemotherapy Improves Survival Outcomes for Patients With Brain Metastasis from Ovarian Cancer
SHINICHI TATE, KYOKO NISHIKIMI, AYUMU MATSUOKA, SATOYO OTSUKA and MAKIO SHOZU

Anticancer Research May 2022, 42 (5) 2637-2644; DOI: https://doi.org/10.21873/anticanres.15741
You have access
Phase II Study of S-1 and Irinotecan Plus Bevacizumab as Second-line Treatment for Patients With Metastatic Colorectal Cancer Resistant to the Fluoropyrimidine-oxaliplatin-cetuximab Regimen
HIROAKI TANIOKA, KEN SHIMADA, AKIHITO TSUJI, MITSUGU KOCHI, HO MIN KIM, TAKAO TAKAHASHI, TADAMICHI DENDA, AKINORI TAKAGANE, TAKANORI WATANABE, MASAHITO KOTAKA, MASATO NAKAMURA, YU SUNAKAWA, MASAHIRO TAKEUCHI, WATARU ICHIKAWA and MASASHI FUJII

Anticancer Research May 2022, 42 (5) 2675-2681; DOI: https://doi.org/10.21873/anticanres.15745
You have access
A Case of Rare Matrix-producing Triple-negative Breast Carcinoma for Which Drug Response in a Patient-derived Orthotopic Xenograft Mouse Model Was Correlated With Patient Response
TSUNEHISA NOMURA, JUNICHI KUREBAYASHI, TAKUYA MORIYA, WATARU SAITO, TAKUYA MURATA, JUN YAMAMOTO, CHIHIRO HOZUMI and ROBERT M. HOFFMAN

Anticancer Research December 2021, 41 (12) 6191-6197; DOI: https://doi.org/10.21873/anticanres.15438
You have access
Randomized Clinical Trials and Real World Prospective Observational Studies on Bevacizumab, PARP Inhibitors, and Immune Checkpoint Inhibitors in the First-Line Treatment of Advanced Ovarian Carcinoma: A Critical Review
ANGIOLO GADDUCCI and STEFANIA COSIO

Anticancer Research October 2021, 41 (10) 4673-4685; DOI: https://doi.org/10.21873/anticanres.15281
You have access
Risk–benefit Analysis of FOLFIRI Plus Ramucirumab/Aflibercept as a Third-line Treatment in Metastatic Colorectal Cancer
MICHIO KIMURA, EISEKI USAMI, HITOMI TERAMACHI and TOMOAKI YOSHIMURA

Anticancer Research June 2021, 41 (6) 3091-3097; DOI: https://doi.org/10.21873/anticanres.15093
You have access
The Pre-treatment Lymphocyte-to-Monocyte Ratio Predicts Efficacy in Metastatic Colorectal Cancer Treated With TAS-102 and Bevacizumab
HIDEKAZU KURAMOCHI, TAKESHI YAMADA, YOICHIRO YOSHIDA, AKIHISA MATSUDA, HIROHIKO KAMIYAMA, CHIHIRO KOSUGI, KEIICHIRO ISHIBASHI, ATSUKO FUKAZAWA, KEISUKE IHARA, HIROMICHI SONODA, KAZUHIKO YOSHIMATSU, HIROSHI YOSHIDA, SUGURU HASEGAWA, KAZUHIRO SAKAMOTO, HIDEYUKI ISHIDA, KEIJI KODA and On behalf of the TAS CC3 Study Group

Anticancer Research June 2021, 41 (6) 3131-3137; DOI: https://doi.org/10.21873/anticanres.15098
You have access
Comparison of Chemotherapeutic Regimens Frequently Used in Metastatic Non-squamous NSCLC Treatment
DANIEL KREJCI, PETR OPALKA, JANA KREJCI, MILADA ZEMANOVA, PETRA ZEMANOVA, JURAJ KULTAN, ONDREJ FISCHER, JANA SKRICKOVA, MONIKA BRATOVA, MARKETA CERNOVSKA, MICHAL HRNCIARIK, HELENA COUPKOVA, KAROLINA HURDALKOVA, MAGDA BARINOVA, LEONA KOUBKOVA, DANIEL DOLEZAL, MARTIN SAFANDA, MILOS PESEK and MARTIN SVATON

Anticancer Research May 2021, 41 (5) 2597-2603; DOI: https://doi.org/10.21873/anticanres.15039
You have access
Prognostic Role for CYFRA 21-1 in Patients With Advanced-stage NSCLC Treated With Bevacizumab Plus Chemotherapy
MARTIN SVATON, JIRI BLAZEK, GABRIELA KRAKOROVA, MILOS PESEK, MARCELA BURESOVA, ZUZANA TEUFELOVA, JOSEF VODICKA, KAROLINA HURDALKOVA, MAGDA BARINOVA and ONDREJ TOPOLCAN

Anticancer Research April 2021, 41 (4) 2053-2058; DOI: https://doi.org/10.21873/anticanres.14974
You have access
Prospective Multicenter Phase II Study of Biweekly TAS-102 and Bevacizumab for Metastatic Colorectal Cancer
TETSUO ISHIZAKI, JUNICHI MAZAKI, MASANOBU ENOMOTO, MASATOSHI SHIGOKA, KENTA KASAHARA, TAKAAKI MATSUDO, HIDEAKI KAWAKITA, YUICHI NAGAKAWA, KENJI KATSUMATA and AKIHIKO TSUCHIDA

Anticancer Research April 2021, 41 (4) 2157-2163; DOI: https://doi.org/10.21873/anticanres.14988

Main menu

User menu

Search

Bevacizumab

Pages